Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Congestive heart failure (heart failure) report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.
Key Targets in the Heart Failure Pipeline Market
The key targets in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1, Beta 1 Adrenergic Receptor, Sodium/Glucose Cotransporter 2, Mineralocorticoid Receptor, Beta 2 Adrenergic Receptor, Myosin, and Beta 3 Adrenergic Receptor. Atrial Natriuretic Peptide Receptor 1 has the highest pipeline products.
Heart Failure Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Heart Failure Pipeline Market
The key MoA in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1 Agonist, Sodium/Glucose Cotransporter 2 Inhibitor, Mineralocorticoid Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Beta 3 Adrenergic Receptor Antagonist, and Myosin Activator. Atrial Natriuretic Peptide Receptor 1 Agonist have the highest number of pipeline products.
Heart Failure Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Heart Failure Pipeline Market
The key RoA in the heart failure pipeline market are oral, intravenous, subcutaneous, parenteral, intracardiac, intracoronary, and intravenous drip. Oral has the highest number of pipeline products.
Heart Failure Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Heart Failure Pipeline Market
The key molecule types in the heart failure pipeline market are small molecule, cell therapy, gene therapy, synthetic peptide, oligonucleotide, fusion protein, and monoclonal antibody. Small molecule has the highest number of pipeline products in the heart failure pipeline market.
Heart Failure Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Heart Failure Pipeline Market
The key companies in the heart failure pipeline market are AstraZeneca Plc, Bristol-Myers Squibb Co, Bayer AG, Renova Therapeutics Inc, Celixir Ltd, Cytokinetics Inc, Saillant Therapeutics BV, and Sarfez Pharmaceuticals Inc. AstraZeneca Plc has the highest number of pipeline products.
Heart Failure Pipeline Market, by Companies
To know about more companies, download a free report sample
Market report overview
| Key targets | Atrial Natriuretic Peptide Receptor 1, Beta 1 Adrenergic Receptor, Sodium/Glucose Cotransporter 2, Mineralocorticoid Receptor, Beta 2 Adrenergic Receptor, Myosin, and Beta 3 Adrenergic Receptor |
| Key MoA | Atrial Natriuretic Peptide Receptor 1 Agonist, Sodium/Glucose Cotransporter 2 Inhibitor, Mineralocorticoid Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Beta 3 Adrenergic Receptor Antagonist, and Myosin Activator |
| Key RoA | Oral, Intravenous, Subcutaneous, Parenteral, Intracardiac, Intracoronary, and Intravenous Drip |
| Key molecule types | Small Molecule, Cell Therapy, Gene Therapy, Synthetic Peptide, Oligonucleotide, Fusion Protein, and Monoclonal Antibody |
| Key companies | AstraZeneca Plc, Bristol-Myers Squibb Co, Bayer AG, Renova Therapeutics Inc, Celixir Ltd, Cytokinetics Inc, Saillant Therapeutics BV, and Sarfez Pharmaceuticals Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Congestive Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Congestive Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key targets in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1, Beta 1 Adrenergic Receptor, Sodium/Glucose Cotransporter 2, Mineralocorticoid Receptor, Beta 2 Adrenergic Receptor, Myosin, and Beta 3 Adrenergic Receptor.
The key MoA in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1 Agonist, Sodium/Glucose Cotransporter 2 Inhibitor, Mineralocorticoid Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Beta 3 Adrenergic Receptor Antagonist, and Myosin Activator.
The key RoA in the heart failure pipeline market are oral, intravenous, subcutaneous, parenteral, intracardiac, intracoronary, and intravenous drip.
The key molecule types in the heart failure pipeline market are small molecule, cell therapy, gene therapy, synthetic peptide, oligonucleotide, fusion protein, and monoclonal antibody.
The key companies in the heart failure pipeline market are AstraZeneca Plc, Bristol-Myers Squibb Co, Bayer AG, Renova Therapeutics Inc, Celixir Ltd, Cytokinetics Inc, Saillant Therapeutics BV, and Sarfez Pharmaceuticals Inc.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Cardiovascular reports